uploads///molecule _

Taking Stock of Ionis’s Performance

By

Dec. 14 2018, Updated 2:59 p.m. ET

An overview of Ionis

Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake. In its Core Ionis segment, the company is using its antisense technology to develop a pipeline of best-in-class drugs.

Akcea is focused on the development of drugs targeted at treating rare and serious diseases. In this series, we’ll explore Ionis’s financials and valuations and analysts’ views on its stock.

Article continues below advertisement

Ionis’s top line

In the third quarter of this year, Ionis’s total revenue rose YoY (year-over-year) to $145.4 million from $118.31 million.

The company generates revenue from Spinraza royalties, licensing and other royalties, and research and development revenue under collaborative agreements. Its Spinraza royalties increased YoY to $70.01 million from $32.89 million. Its licensing and other royalty revenues rose YoY to $12.75 million from $1.73 million. Ionis’s research and development revenue under collaborative agreements fell YoY to $62.64 million from $83.7 million.

Revenue forecast

In 2018 and 2019, Ionis Pharmaceuticals is expected to generate revenues of $604.99 million and $823.25 million, respectively, compared to $507.67 million in 2017. Meanwhile, peers Eli Lilly and Company (LLY), Merck & Co. (MRK), and Pfizer (PFE) are expected to see revenues of $24.42 billion, $42.31 billion, and $53.59 billion, respectively, in 2018. Ionis’s cash per share is $13.50, while Eli Lilly, Merck, and Pfizer have cash per share of $8.36, $3.87, and $2.90, respectively.

Valuation metrics

Ionis’s EV (enterprise value) is $6.17 billion, and its EV-to-revenue ratio is 10.84x. The stock’s forward PE ratio is 124.35x, its price-to-sales ratio is 13.38x, and its price-to-book ratio is 10.78x. Eli Lilly’s, Merck’s, and Pfizer’s price-to-book ratios are 8.96x, 6.49x, and 3.67x, respectively. Next, we’ll look at Ionis’s operational performance.

Advertisement

More From Market Realist

  • Delta aircraft
    Company & Industry Overviews
    Delta Air Lines Updates Mandatory Vaccine Policy, Explained
  • AMC advertisement in walkway
    Company & Industry Overviews
    Why It's Time for Most Investors to Sell AMC Entertainment Stock
  • 100 Thieves founder Matthew Haag
    Company & Industry Overviews
    Why Growing Esports Company 100 Thieves Isn't Publicly Traded
  • Bitski art and logo
    Company & Industry Overviews
    NFT Platform Provider Bitski Isn’t Publicly Traded
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.